The court ruled that the company's director acted in "good faith" and did not "breach a fiduciary duty owed to the corporation or any of its equity security holders." * Gilead Sciences Inc., of Foster City, Calif., has received marketing authorization for Vistide (cidofovir injection) from the European Commission, which allows the product to be marketed in all 15 countries of the European Union as an intravenous treatment for cytomegalovirus (CMV) retinitis in patients with AIDS. * Hybridon

Earlier this month, the EPO, which regulates patents in 15 European Union member countries, acceded to a request from Berlin-based Schering to revoke Biogen's production patent for Avonex, its Interferon beta-1a treatment for multiple sclerosis

LeukoScan, which provides a one-step, rapid method of locating sites of infection within the body, received final clearance from the European Commission in February for sale in the European Union. * SuperGen Inc., of San Ramon, Calif., has negotiated a letter of intent for an ongoing source of bulk paclitaxel (sold as Taxol by Bristol-Myers Squibb, of New York), which will provide the company with commercial quantities of the drug

Atrix also said it received a $100,000 grant from the National Institutes of Health to develop its biodegradable polymers for delivering bone morphogenetic proteins to treat bone degeneration. * Chiron Corp., of Emeryville, Calif., said its Chiron Vision business unit received European Union approval for Vitrasert Implant to treat cytomegalovirus retinitis in AIDS patients

Bromocriptine is a generic dopamine agonist approved by the FDA for treatment of Parkinson's disease. * Gilead Sciences Inc., of Foster City, Calif., and its partner, Pharmacia & Upjohn Inc., of Kalamazoo, Mich., said Vistide (cidofovir injection) has been recommended for marketing approval for AIDS-related cytomegalovirus retinitis by the European Union's Committee for Proprietary Medicinal Products

and the European Union's 15 nations. * The Liposome Company Inc., of Princeton, N.J., completed a call for redemption of its 7.75 percent convertible exchangeable preferred stock

Immunomedics Inc., of Morris Plains, N.J., received clearance from the European Commission to market CEA-Scan (arcitumomab) for detection of colorectal cancer in the European Union's 15 countries

DNX's chairman, president and CEO, Paul Schmitt, will retain those posts with the combined firm. * Genzyme Corp., of Cambridge, Mass., said the European Union has approved Sepracoat, which is designed to prevent post-surgical adhesions in abdominal, pelvic and thoracic operations

The company has a platform in protein-based enzymes that helps in the discovery of catalysts for chemical synthesis, industrial processes and pharmacological uses. * Sequus Pharmaceuticals Inc., of Menlo Park, Calif., received European Union marketing authorization for Doxil, or liposomal doxorubicin

Enrollment has begun in the 560-patient study sponsored by the National Institute of Allergy and Infectious Diseases. * Rhone-Poulenc Rorer Inc., of Collegeville, Pa., said Rilutek was cleared for marketing as a treatment for amyotrophic lateral sclerosis in the European Union's 15 member countries. * Scios Inc., of Mountain View, Calif., said the Opposition Division of the European Patent Office (EPO) ruled in its favor in an opposition related to Fiblast trafermin, the company's recombinant

Enrollment has begun in the 560-patient study sponsored by the National Institute of Allergy and Infectious Diseases. * Rhone-Poulenc Rorer Inc., of Collegeville, Pa., said Rilutek was cleared for marketing as a treatment for amyotrophic lateral sclerosis in the European Union's 15 member countries. * Scios Inc., of Mountain View, Calif., said the Opposition Division of the European Patent Office (EPO) ruled in its favor in an opposition related to Fiblast trafermin, the company's recombinant

Enrollment has begun in the 560-patient study sponsored by the National Institute of Allergy and Infectious Diseases. * Rhone-Poulenc Rorer Inc., of Collegeville, Pa., said Rilutek was cleared for marketing as a treatment for amyotrophic lateral sclerosis in the European Union's 15 member countries. * Scios Inc., of Mountain View, Calif., said the Opposition Division of the European Patent Office (EPO) ruled in its favor in an opposition related to Fiblast trafermin, the company's recombinant

Gilead's most advanced drug is an injectable form of cidofovir, called Vistide, which is under review by the FDA and European Union for cytomegalovirus retinitis in AIDS patients. * SangStat Medical Corp., of Menlo Park, Calif., reacquired rights to pre-transplant monitoring products from Baxter Healthcare Corp., of Deerfield, Ill. Financial details were not disclosed

Trials are ongoing in several cancers. * Immunomedics Inc., of Morris Plains, N.J., said the European Union's (EU) Committee for Proprietary Medicinal Products (CPMP) recommended approval of the company's CEA-Scan diagnostic imaging agent for colorectal cancer

The company has about 13.6 million shares outstanding. * BioChem Pharma Inc., of Laval, Quebec, said the European Union's Committee for Proprietary Medicinal Products recommended approval of Epivir, or 3TC, for AIDS

Molecular Biosystems Inc., of San Diego, received notification from European regulatory authorities that the ultrasound contrast agent Albunex (Infoson in Europe) was recommended for approval in the European Union

Immune Response Corp., of Carlsbad, Calif., said the FDA has approved its manufacturing process for the company's HIV-1 immunogen, called Remune, clearing the way for continued clinical trials of the AIDS vaccine. * NeXstar Pharmaceuticals Inc., of Boulder, Colo., said 10 additional countries of the European Union have approved DaunoXome, a liposomal form of daunorubicin, for AIDS-related Kaposi's sarcoma

Pharmacia Biotech is a subsidiary of Pharmacia & Upjohn Co., of Kalamazoo, Mich. * Immune Response Corp., of Carlsbad, Calif., said the FDA has approved its manufacturing process for the company's HIV-1 immunogen, called Remune, clearing the way for continued clinical trials of the AIDS vaccine. * NeXstar Pharmaceuticals Inc., of Boulder, Colo., said 10 additional countries of the European Union have approved DaunoXome, a liposomal form of daunorubicin, for AIDS-related Kaposi's sarcoma

Total net proceeds for MedImmune from the offering, priced at $18 per share, were about $58.4 million. (See BioWorld Today, Feb. 15, p. 1.) * Sequus Pharmaceuticals Inc., of Menlo Park, received European Union approval of Doxil, a liposomal form of doxorubicin, as a first- and second-line therapy against AIDS related Kaposi's sarcoma